Samrat Pharmachem Ltd Financials

Samrat Pharmachem Ltd Financial Statement

Samrat Pharmachem Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Sep 2024	Jun 2024	Mar 2024
Revenue	70.66	81.41	82.98
Operating Expense	66.81	78.24	81.33
Net Profit	2.66	2.07	1.40
Net Profit Margin	3.76	2.54	1.69
Earning Per Share	8.60	6.68	4.52
EBIDTA	4.43	3.02	1.59
Effective Tax Rate	37.14	18.93	-4.85

Particulars	Sep 2024
Revenue	70.66
Operating Expense	66.81
Net Profit	2.66
Net Profit Margin	3.76
Earning Per Share	8.60
EBIDTA	4.43
Effective Tax Rate	37.14

Samrat Pharmachem Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Total Revenue Annual	281.58	310.65	221.75
Operating Expenses Annual	279.11	286.72	197.51
Operating Profit Annual	3.85	24.41	24.87
Interest Annual	0.69	1.23	0.67
Depreciation	0.65	0.64	0.59
Net Profit Annual	2.16	16.63	17.18
Tax Annual	0.36	5.90	6.42

Particulars	Mar 2024
Total Revenue Annual	281.58
Operating Expenses Annual	279.11
Operating Profit Annual	3.85
Interest Annual	0.69
Depreciation	0.65
Net Profit Annual	2.16
Tax Annual	0.36

Samrat Pharmachem Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Cash Flow at the Beginning	11.86	14.71	0.24
Cash Flow from Operations	9.41	-9.44	17.47
Cash Flow from Investing	-0.41	-3	-1.06
Cash Flow from Financing	-11.20	9.60	-1.95
Cash Flow at the End	9.67	11.86	14.71

Particulars	Mar 2024
Cash Flow at the Beginning	11.86
Cash Flow from Operations	9.41
Cash Flow from Investing	-0.41
Cash Flow from Financing	-11.20
Cash Flow at the End	9.67

Samrat Pharmachem Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
PBDIT Margin (%)	1.37	7.85	11.22
PBIT Margin (%)	1.14	7.65	10.95
PBT Margin (%)	-0.51	1.43	-5.38
Net PROFIT Margin (%)	0.77	5.35	7.75
Return On Networth / Equity (%)	3.37	30.25	44.94
Return On Networth /Employed (%)	4.14	34.91	52.32
Return On Assets (%)	2.78	24.41	37.03
Total Debt / Equity (X)	0.21	0.24	0.21
Asset Turnover Ratio (%)	3.63	4.56	4.78

Particulars	Mar 2024
PBDIT Margin (%)	1.37
PBIT Margin (%)	1.14
PBT Margin (%)	-0.51
Net PROFIT Margin (%)	0.77
Return On Networth / Equity (%)	3.37
Return On Networth /Employed (%)	4.14
Return On Assets (%)	2.78
Total Debt / Equity (X)	0.21
Asset Turnover Ratio (%)	3.63

Samrat Pharmachem Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2024	Mar 2023	Mar 2022
Fixed Assets Annual	10.72	10.70	9.99
Total Current Assets Annual	102.57	99.05	71.26
Non Current Assets Annual	19.17	17.54	13.35
Total Shareholders Funds Annual	65.00	63.14	46.82
Total Assets Annual	121.74	116.59	84.61

Particulars	Mar 2024
Fixed Assets Annual	10.72
Total Current Assets Annual	102.57
Non Current Assets Annual	19.17
Total Shareholders Funds Annual	65.00
Total Assets Annual	121.74

Samrat Pharmachem Ltd Earning Calls

No Data Availabe

Dividend Pages

PE Ratio

Get Your FAQs Right

As of Dec 26, 2024, Samrat Pharmachem Ltd has a market capitalization of 103.04 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Samrat Pharmachem Ltd is debt-free with a debt-to-equity ratio of 0.13.

In FY 2023 , Samrat Pharmachem Ltd recorded a total revenue of approximately 281.58 Cr marking a significant milestone in the company's financial performance.

Samrat Pharmachem Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.2% and 0.1% annually, respectively..

Samrat Pharmachem Ltd's current PE ratio is 47.70.

Samrat Pharmachem Ltd's ROCE averaged 26.0% from the FY ending March 2022 to 2024, with a median of 29.0%. It peaked at 44.7% in March 2022, reflecting strong capital efficiency over the period..

Samrat Pharmachem Ltd's latest EBIT is Rs. 3.21 Cr, surpassing the average EBIT of Rs. 17.08 Cr over the 5 years..